Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio | Nyxoah

▤ Summary

Nyxoah secured financing commitments of up to U.S. $77 million through a private placement, a registered direct offering, and a convertible bond. The company plans to use the proceeds to accelerate U.S. commercialization of its Genio sleep apnea system and expand in initial markets outside the U.S. It will also fund clinical data generation, physician-led research, product redesign, and manufacturing cost reduction efforts. The company named several strategic investors, including Cochlear, Resmed, and its own leadership team. The transaction closes in stages, with the equity pieces expected to close in November 2025 and the first bond tranche in December 2025.

$ Funding

▦ Linked Companies